← Leaderboards
Wen Jiang
Ut Southwestern Medical Center
$5,217,879
Attributed
$7,503,878
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.8M · FY2019–25$5M$3.8M$2.5M$1.3M$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,503,878 · 6
By mechanism
R01$6,323,084 · 4
K08$760,131 · 1
R21$420,663 · 1
Top collaborators
- Betty Kim6 shared
- Zhaogang Yang2 shared
Others in their field
Other Emerging Leaders on “Antibodies”
- Bambra Strokes · Ppd Development Lp$461,655,950
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$169,304,044
- Yunda Huang · Fred Hutchinson Cancer Center$73,421,550
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Hanjoon Ryu$28,519,898
- Wendy Sammons-Jackson · National Institute Of Allergy And Infectious Diseases$27,369,420
Research focus
AntibodiesTumorCellsImmuneReceptorMediatingProductionPhagocytosisCancer ImmunotherapyT-LymphocyteAntitumor ResponsePathway InteractionsMacrophagePhagocytesImmune SystemMalignant Breast NeoplasmTumor GrowthReconstitutionImmune Checkpoint BlockadeAntigensIn VivoPre-Clinical ModelDesignMalignant Neoplasms
Grant awards (16)
Engineering In Vivo Chimeric Antigen Receptor Macrophages (CARMs) using mRNA-exosomes for Cancer Immunotherapy$1,135,633
R01 · FY2025 · CA · contact PI
Engineering mRNA encapsulated extracellular vesicles for in vivo chimeric antigen receptor macrophage therapy for glioblastoma$645,873
R01 · FY2025 · CA · contact PI
Microbial-inspired immune-stimulating antibody-toxin conjugate (ATC) for cancer immunotherapy$616,715
R01 · FY2025 · CA
Therapeutic targeting of multiple glioblastoma phagocytosis checkpoints using a novel bispecific antibody$435,054
R01 · FY2025 · NS · contact PI
Engineering mRNA encapsulated extracellular vesicles for in vivo chimeric antigen receptor macrophage therapy for glioblastoma$645,873
R01 · FY2024 · CA · contact PI
Engineering In Vivo Chimeric Antigen Receptor Macrophages (CARMs) using mRNA-exosomes for Cancer Immunotherapy$539,426
R01 · FY2024 · CA · contact PI
Therapeutic targeting of multiple glioblastoma phagocytosis checkpoints using a novel bispecific antibody$422,003
R01 · FY2024 · NS · contact PI
Engineering In Vivo Chimeric Antigen Receptor Macrophages (CARMs) using mRNA-exosomes for Cancer Immunotherapy$567,816
R01 · FY2023 · CA · contact PI
Therapeutic targeting of multiple glioblastoma phagocytosis checkpoints using a novel bispecific antibody$435,054
R01 · FY2023 · NS · contact PI
Therapeutic targeting of multiple glioblastoma phagocytosis checkpoints using a novel bispecific antibody$435,054
R01 · FY2022 · NS · contact PI
Therapeutic targeting of multiple glioblastoma phagocytosis checkpoints using a novel bispecific antibody$444,583
R01 · FY2021 · NS · contact PI
A Phagocytosis Modulating Nanomedicine for Targeted Breast Cancer Immunotherapy$253,377
K08 · FY2021 · CA · contact PI
Renal Cell Carcinoma Surveillance by Immuno-Lipoplex Nanoparticle Platform$191,529
R21 · FY2021 · CA
A Phagocytosis Modulating Nanomedicine for Targeted Breast Cancer Immunotherapy$253,377
K08 · FY2020 · CA · contact PI
Renal Cell Carcinoma Surveillance by Immuno-Lipoplex Nanoparticle Platform$229,134
R21 · FY2020 · CA
A Phagocytosis Modulating Nanomedicine for Targeted Breast Cancer Immunotherapy$253,377
K08 · FY2019 · CA · contact PI